AstraZeneca and the University of Cambridge Judge Business School today announced an agreement to deliver a new “Accelerate Cambridge Life Sciences” programme at the business school which will identify, train and mentor start-up ventures in the life sciences.
The partnership underlines the commitment of both AstraZeneca and Cambridge Judge Business School to scientific enterprise and innovation in the Cambridge area where AstraZeneca is building a new global R&D centre and corporate headquarters, and where Cambridge Judge Business School plans to expand its historic building space. It also reinforces AstraZeneca’s long-term commitment to supporting bioscience research in the UK.
Christoph Loch, director of Cambridge Judge Business School, said:
Inspiring and promoting entrepreneurship form a central part of the Cambridge Judge mission. This agreement with AstraZeneca will help a new generation of life science ventures benefit from the rich and varied expertise that Cambridge provides. We are really proud to organise and host the new Accelerate Cambridge Life Sciences programme.
Menelas Pangalos, Executive Vice President of Innovative Medicines & Early Development at AstraZeneca, commented:
We are proud to be the first life science partner for Cambridge Judge Business School’s Accelerate programme. Having access to support and guidance from experienced AstraZeneca employees will not only be invaluable for the participants as they develop their new ventures, but will also be great for our people who will gain exposure to early stage innovation and entrepreneurial thinking outside AstraZeneca.
Celebrating 25 years of excellence
Cambridge Judge Business School, celebrating its 25th anniversary this year, leverages the power of academia for real-world impact. Throughout the rest of the year, we are highlighting some of the recent initiatives that demonstrate our impact on people, institutions and society at large. Find out more about our 25th anniversary